Potentiation of oral anticoagulation and hemarthrosis associated with nabumetone

Pharmacotherapy

Volumn 20, Issue 2, 2000, Pages 234-239

  Dennis, Vincent C ^a,b   Thomas, Brian K ^a   Hanlon, James E ^b  

^a UNIVERSITY OF OKLAHOMA HEALTH SCIENCES CENTER   (United States)

^b Norman Regional Hospital   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; DIGOXIN; GLYCERYL TRINITRATE; HYOSCYAMINE; MULTIVITAMIN; NABUMETONE; QUINIDINE; RANITIDINE; WARFARIN; ZOLPIDEM;

AGED; ANTICOAGULANT THERAPY; ARTICLE; BLEEDING TENDENCY; CASE REPORT; DRUG MONITORING; DRUG POTENTIATION; DRUG RESPONSE; HEART ATRIUM FIBRILLATION; HEMARTHROSIS; HUMAN; KNEE; MALE; TRANSIENT ISCHEMIC ATTACK;

EID: 0033983322     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.20.3.234.34789     Document Type: Article

References (31)

1. Wells PS, Hollbrook AM, Crowther NR, Hirsh J. Interactions of warfarin with drugs and food. Ann Intern Med 1994;121:676-83.
2. Levine MN, Raskob G, Landefeld S, Kearon C. Hemorrhagic complications of anticoagulant treatment. Chest 1998;114(suppl):511-23.
3. O'Callaghan JW, Thompson RN, Russell AS. Combining NSAIDs with anticoagulants: yes and no. Can Med Assoc J 1984;131:857-9.
4. Chan TYK. Adverse interactions between warfarin and nonsteroidal antiinflammatory drugs: mechanisms, clinical significance, and avoidance. Ann Pharmacother 1995;29:1274-83.
5. Koch-Weser J, Sellers EM. Drug interactions with coumarin anticoagulants [two parts]. N Engl J Med 1971;285:487-98, 547-58.
6. MacLeod SM, Sellers EM. Pharmacodynamic and pharmacokinetic drug interactions with coumarin anticoagulants. Drugs 1976;11:461-70.
7. Nunn B, Chamberlain PD. Effect of nabumetone (BRL 14777), a new anti-inflammatory drug, on human platelet reactivity ex vivo: comparison with naproxen. J Pharm Pharmacol 1982;34:576-9.
8. Greb WH, von Schrader HW, Cerlek S, Dominis M, Hauptmann E, Zenic N. Endoscopic studies of nabumetone in patients with rheumatoid arthritis: a comparative endoscopic and histologic evaluation. Am J Med 1987;83(suppl 4B):19-24.
9. McLaughlin GE, McCarty DJ, Segal BL. Hemarthrosis complicating anticoagulant therapy. JAMA 1966;196:1020-1.
10. Wild JH, Zvaifler NJ. Hemarthrosis associated with sodium warfarin therapy. Arthritis Rheum 1976;19:98-102.
11. Hasselbacher P, Schimmer BM, Weinberger A. Hemarthrosis with sodium warfarin and heparin. Arthritis Rheum 1978;21:740.
12. Andes WA, Edmunds JO. Hemarthroses and warfarin: joint destruction with anticoagulation. Thromb Haemost 1983;49:187-9.
13. Neuzil KM. Hemarthrosis and oral anticoagulants. J Tenn Med Assoc 1991;84:180-1.
14. Jaffer AM, Schmid FR. Hemarthrosis associated with sodium warfarin. J Rheumatol 1977;4:215-17.
15. Ames PRJ, Maffulli N, Capasso G, Brancaccio V. Minimal trauma knee hemarthrosis. Bull Hosp Joint Dis 1996;54:258-60.
16. Buckley NA, Dawson AH. Drug interactions with warfarin. Med J Aust 1992;157:479-83.
17. Tonkin AL, Wing LMH. Interactions of non-steroidal anti-inflammatory drugs. Baillieres Clin Rheumatol 1988;2:455-83.
18. Diana FJ, Veronich K, Kapoor AL. Binding of nonsteroidal anti-inflammatory agents and their effect on binding of racemic warfarin and its enantiomers to human serum albumin. J Pharm Sci 1989;78:195-9.
19. MacKichan JJ. Protein binding drug displacement interactions. Fact or fiction? Clin Pharmacokinet 1989;16:65-73.
20. Penner JA, Abbrecht PH. Lack of interaction between ihuprofen and warfarin. Curr Ther Res 1975;18:862-71.
21. Jain A, McMahon FG, Slattery JT, Levy G. Effect of naproxen on the steady-state serum concentration and anticoagulant activity of warfarin. Clin Pharmacol Ther 1979;25:61-6.
22. Holmes EL. Pharmacology of the fenamates. IV. Toleration by normal human subjects. Ann Phys Med 1966;8(suppl):36-49.
23. SmithKline Beecham Pharmaceuticals. Relafen (nabumetone) package insert. Philadelphia, PA;1999.
24. Fitzgerald DE. Double-blind study to establish whether there is any interaction between nabumetone and warfarin in healthy adult male volunteers. In: Panayi GS, Price JD, Rotman H, eds. Nabumetone, a novel anti-inflammatory, vol. 69. London: Royal Society of Medicine, 1985:47-52.
25. Hilleman DE, Mohiuddin SM, Lucas BD. Hypoprothromhinemic effect of nabumetone in warfarin-treated patients [abstr]. Pharmacotherapy 1993;13:270-1.
26. Hilleman DE, Mohiuddin SM, Lucas BD. Nonsteroidal antiinflammatory drug use in patients receiving warfarin: emphasis on nabumetone. Am J Med 1993;95:30s-4.
27. Hirsh J, Dalen JE, Anderson DR, et al. Oral anticoagulants: mechanism of action, clinical effectiveness, and optimal therapeutic range. Chest 1998;114(suppl):445-69.
28. Kaplan-Machlis B, Klostermeyer BS. The cyclooxygenase-2 inhibitors: safety and effectiveness. Ann Pharmacother 1999;33:979-88.
29. Merck & Co., Inc. Vioxx (rofecoxib) package insert. West Point, PA;1999.
30. G. D. Searle & Co. Celebrex (celecoxib) package insert. Chicago, IL; 1999.
31. Mohammed S, Croom DW. Gastropathy due to celecoxib, a cyclooxygenase-2 inhibitor. N Engl J Med 1999;25:2005.